MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Aktien・Vivani Medical

Vivani Medical

Geschlossen

1.33 3.1

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.3

Max

1.34

Schlüsselkennzahlen
By Trading Economics
Einkommen	-103K -6.6M
Angestellte	42

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+186.26% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	11. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-2.2M 71M
Vorheriger Eröffnungskurs	-1.77
Vorheriger Schlusskurs	1.33

Vivani Medical Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Apr. 2026, 20:26 UTC

Akquisitionen, Fusionen, Übernahmen

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17. Apr. 2026, 18:15 UTC

Wichtige Nachrichtenereignisse

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17. Apr. 2026, 16:49 UTC

Wichtige Nachrichtenereignisse

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17. Apr. 2026, 16:49 UTC

Wichtige Nachrichtenereignisse

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17. Apr. 2026, 22:58 UTC

Ergebnisse

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17. Apr. 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17. Apr. 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Apr. 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17. Apr. 2026, 20:52 UTC

Ergebnisse

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17. Apr. 2026, 20:50 UTC

Market Talk

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

17. Apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Apr. 2026, 20:29 UTC

Ergebnisse

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17. Apr. 2026, 20:11 UTC

Akquisitionen, Fusionen, Übernahmen

UCB to Buy Neurona Therapeutics for Up to $1.15B

17. Apr. 2026, 19:34 UTC

Market Talk

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

17. Apr. 2026, 19:34 UTC

Market Talk

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17. Apr. 2026, 19:31 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17. Apr. 2026, 19:26 UTC

Market Talk

U.S. Natural Gas Futures Edge Up -- Market Talk

17. Apr. 2026, 19:21 UTC

Market Talk

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17. Apr. 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17. Apr. 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17. Apr. 2026, 18:57 UTC

Wichtige Nachrichtenereignisse

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17. Apr. 2026, 18:53 UTC

Akquisitionen, Fusionen, Übernahmen

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17. Apr. 2026, 18:53 UTC

Akquisitionen, Fusionen, Übernahmen

UCB 2026 Rev Guidance Unchanged

17. Apr. 2026, 18:52 UTC

Akquisitionen, Fusionen, Übernahmen

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17. Apr. 2026, 18:52 UTC

Akquisitionen, Fusionen, Übernahmen

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17. Apr. 2026, 18:14 UTC

Market Talk

Wichtige Nachrichtenereignisse

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17. Apr. 2026, 18:00 UTC

Wichtige Nachrichtenereignisse

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17. Apr. 2026, 18:00 UTC

Wichtige Nachrichtenereignisse

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17. Apr. 2026, 17:31 UTC

Market Talk

Wichtige Nachrichtenereignisse

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17. Apr. 2026, 17:26 UTC

Market Talk

Ergebnisse

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Peer-Vergleich

Kursveränderung

Vivani Medical Prognose

Kursziel

By TipRanks

186.26% Vorteil

12-Monats-Prognose

Durchschnitt 3.75 USD 186.26%

Hoch 4 USD

Tief 3.5 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vivani Medical – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Vivani Medical – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Betriebsergebnis

Über Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.